Coty considers sale or spinoff of CoverGirl, WSJ reports-February 2024-www.financetom.com

Coty considers sale or spinoff of CoverGirl, WSJ reports

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Coty considers sale or spinoff of CoverGirl, WSJ reports

Sep 29, 2025 11:15 PM

Sept 30 (Reuters) - Cosmetics-maker Coty ( COTY ) is

conducting a strategic review of CoverGirl and its other

mass-market beauty brands, and will consider options including

selling or spinning them off, the Wall Street Journal reported

on Tuesday, citing a company announcement reviewed by the

newspaper.

Reuters could not immediately verify the report.

Previous page： NEO Battery Materials Raises $0.8-Million as it Closes a Private Placement of Share Units Next page： CenterPoint Energy's Q3 Non-GAAP Earnings Fall, Revenue Unchanged

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

NEO Battery Materials Raises $0.8-Million as it Closes a Private Placement of Share Units

Oct 28, 2024

04:43 PM EDT, 10/28/2024 (MT Newswires) -- NEO Battery Materials ( NBMFF ) after trade Monday said it closed a private placement of share units that raised $0.8 million. The company said it placed two-million units in the financing, with each priced at $0.40 and made up of a share and one half of a two-year warrant to buy a...

CenterPoint Energy's Q3 Non-GAAP Earnings Fall, Revenue Unchanged

Oct 28, 2024

06:49 AM EDT, 10/28/2024 (MT Newswires) -- CenterPoint Energy ( CNP ) reported Q3 non-GAAP earnings Monday of $0.31 per diluted share, down from $0.40 a year earlier. Analysts polled by Capital IQ expected $0.31. Total revenue for the quarter ended Sept. 30 was $1.86 billion, unchanged from a year earlier. Analysts surveyed by Capital IQ expected $1.90 billion. For...

Merck, Moderna Begin Phase 3 Trial of V940, Keytruda Combination

Oct 28, 2024

07:34 AM EDT, 10/28/2024 (MT Newswires) -- Merck ( MRK ) and Moderna ( MRNA ) said Monday it initiated a phase 3 trial evaluating the investigational V940 in combination with Keytruda to treat certain types of non-small cell lung cancer. The first patients in the trial were enrolled in Canada. Price: 104.15, Change: +0.17, Percent Change: +0.16 ...

Toyota, NTT to make $3.3 bln R&D investment for AI self-driving, Nikkei reports

Oct 28, 2024

Oct 29 (Reuters) - Toyota Motor ( TM ) and Japan's Nippon Telegraph and Telephone ( NPPXF ) will invest 500 billion yen ($3.26 billion) in research and development to create artificial intelligence software to improve self-driving, Nikkei reported on Tuesday. The carmaker and the Tokyo-headquartered telecommunications major are planning to develop automotive software which will use AI to anticipate...